期刊文献+

多发性骨髓瘤骨病的治疗 被引量:7

原文传递
导出
摘要 多发性骨髓瘤(MM)是骨髓中单克隆浆细胞异常增生的恶性肿瘤,骨质损害是MM特征性的临床表现之一,大约75%的MM患者在诊断时即有骨骼浸润,如骨痛,溶骨病变,弥漫性骨质疏松或病理性骨折,几乎所有的患者在临床病程中都会出现骨损害的表现,严重影响了患者的生活质量。由于MM目前尚不能彻底根治,因此,预防和治疗MM骨骼并发症以提高患者的生活质量就显得更加重要。
作者 鲍立 黄晓军
出处 《中华内科杂志》 CAS CSCD 北大核心 2008年第8期681-683,共3页 Chinese Journal of Internal Medicine
基金 卫生部医药卫生科技发展研究中心项目(WKJ2007-3-001) 北京大学人民医院科研与发展基金(RDC2007-47)
  • 相关文献

参考文献20

  • 1Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer,2006,42:1544-1553.
  • 2Tian E, Zhan F, Walker R, et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003, 349 : 2483-2494.
  • 3Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 2005,106:3160-3165.
  • 4Oyajobi BO, Garrett IR, Gupta A, et al. Role of Dickkopf 1 (DKK) in myeloma bone disease and modulation by the proteasome inhibitor Velcade. 26th annual meeting of the American Society of Bone and Mineral Research. Seattle WA, 2004:1011.
  • 5Mukherjee S, Raje N, Patel C, et al. Bortezomib induces proliferation of mesenchymal progenitor cells and promotes differentiation towards osteoblastic lineage. Blood,2006,108:88.
  • 6Kawanabe N, Anderson K, Lorenzo JA. Bortezomib, a novel proteasome inhibitor, approved for use in multiple myeloma, inhibits osteoclast formation and function. 26th annual meeting of the American Society of Bone and Mineral Research. Seattle WA,2004:337.
  • 7Zangari M, Yaccoby S, Cavallo F, et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma, 2006,7 : 109-114.
  • 8Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica, 2006,91 : 192-199.
  • 9Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol, 2006, 77:233-235.
  • 10Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol, 2006, 135 : 688-692.

同被引文献50

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部